ZEPP
ZEPP
Zepp Health CorporationIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $598.12M ▲ | $272.28M ▲ | $-77.05M ▼ | -12.88% ▼ | $-77.12 ▼ | $-27.19M ▼ |
| Q3-2025 | $539.56M ▲ | $212.2M ▲ | $-11.5M ▲ | -2.13% ▲ | $-0.73 ▲ | $6.44M ▲ |
| Q2-2025 | $427.07M ▲ | $198.35M ▼ | $-55.64M ▲ | -13.03% ▲ | $-3.5 ▲ | $-36.2M ▲ |
| Q1-2025 | $279.89M ▼ | $237.76M ▲ | $-143.37M ▲ | -51.23% ▲ | $-9.32 ▲ | $-130.11M ▲ |
| Q4-2024 | $433.03M | $224.49M | $-268.55M | -62.02% | $-16.74 | $-134.28M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $789.7M ▲ | $3.95B ▼ | $2.45B ▼ | $1.5B ▼ |
| Q3-2025 | $446.69M ▼ | $4.17B ▲ | $2.56B ▲ | $1.61B ▼ |
| Q2-2025 | $690.15M ▼ | $3.93B ▲ | $2.32B ▲ | $1.61B ▼ |
| Q1-2025 | $761.42M ▼ | $3.77B ▼ | $2.08B ▲ | $1.69B ▼ |
| Q4-2024 | $815.51M | $3.86B | $2.01B | $1.84B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.5M ▲ | $0 | $0 | $0 | $0 ▲ | $0 |
| Q2-2025 | $-55.64M ▲ | $0 | $0 | $0 | $-61M ▼ | $0 |
| Q1-2025 | $-143.37M ▲ | $0 | $0 | $0 | $-50.1M ▼ | $0 |
| Q4-2024 | $-269.16M ▼ | $0 | $0 | $0 | $0 ▲ | $0 |
| Q3-2024 | $-92.89M | $0 | $0 | $0 | $-6.53M | $0 |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Zepp Health Corporation's financial evolution and strategic trajectory over the past five years.
Zepp combines a sizable revenue base, solid gross margins, and a clearly defined strategic focus on health‑centric wearables and services. Its proprietary operating system, AI chips, biometric sensors, and data algorithms underpin a differentiated ecosystem, while brands like Amazfit and Zepp Clarity give it reach across multiple consumer segments. The balance sheet still shows positive equity and a meaningful cash position, providing some capacity to continue its transformation.
Key risks center on financial sustainability and competitive intensity. The company is currently loss‑making, with negative operating and free cash flow, and relies on a cost base that is heavy relative to revenue. Leverage is meaningful and liquidity is only moderately comfortable, so prolonged cash burn would increase pressure. At the same time, Zepp faces powerful global competitors and rapid innovation cycles, which could compress margins or dilute its differentiation if execution slips.
The outlook depends on whether Zepp can convert its innovation and ecosystem strategy into consistent profitability and cash generation before balance sheet pressures tighten. If it can scale subscription services, better leverage its technology, and bring operating costs in line with its revenue, its health‑focused platform could support a more durable business model. If not, high R&D needs, leverage, and competitive pressure may keep financial performance volatile and uncertain. Overall, the company appears to be in the middle of a strategic transition, with meaningful upside potential but also significant execution and financial risk.
About Zepp Health Corporation
https://www.huami.comZepp Health Corporation, together with its subsidiaries, develops, manufactures, and sells smart wearable technological devices in the People's Republic of China. It operates through two segments, Xiaomi Wearable Products, and Self-Branded Products and Others.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $598.12M ▲ | $272.28M ▲ | $-77.05M ▼ | -12.88% ▼ | $-77.12 ▼ | $-27.19M ▼ |
| Q3-2025 | $539.56M ▲ | $212.2M ▲ | $-11.5M ▲ | -2.13% ▲ | $-0.73 ▲ | $6.44M ▲ |
| Q2-2025 | $427.07M ▲ | $198.35M ▼ | $-55.64M ▲ | -13.03% ▲ | $-3.5 ▲ | $-36.2M ▲ |
| Q1-2025 | $279.89M ▼ | $237.76M ▲ | $-143.37M ▲ | -51.23% ▲ | $-9.32 ▲ | $-130.11M ▲ |
| Q4-2024 | $433.03M | $224.49M | $-268.55M | -62.02% | $-16.74 | $-134.28M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $789.7M ▲ | $3.95B ▼ | $2.45B ▼ | $1.5B ▼ |
| Q3-2025 | $446.69M ▼ | $4.17B ▲ | $2.56B ▲ | $1.61B ▼ |
| Q2-2025 | $690.15M ▼ | $3.93B ▲ | $2.32B ▲ | $1.61B ▼ |
| Q1-2025 | $761.42M ▼ | $3.77B ▼ | $2.08B ▲ | $1.69B ▼ |
| Q4-2024 | $815.51M | $3.86B | $2.01B | $1.84B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.5M ▲ | $0 | $0 | $0 | $0 ▲ | $0 |
| Q2-2025 | $-55.64M ▲ | $0 | $0 | $0 | $-61M ▼ | $0 |
| Q1-2025 | $-143.37M ▲ | $0 | $0 | $0 | $-50.1M ▼ | $0 |
| Q4-2024 | $-269.16M ▼ | $0 | $0 | $0 | $0 ▲ | $0 |
| Q3-2024 | $-92.89M | $0 | $0 | $0 | $-6.53M | $0 |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Zepp Health Corporation's financial evolution and strategic trajectory over the past five years.
Zepp combines a sizable revenue base, solid gross margins, and a clearly defined strategic focus on health‑centric wearables and services. Its proprietary operating system, AI chips, biometric sensors, and data algorithms underpin a differentiated ecosystem, while brands like Amazfit and Zepp Clarity give it reach across multiple consumer segments. The balance sheet still shows positive equity and a meaningful cash position, providing some capacity to continue its transformation.
Key risks center on financial sustainability and competitive intensity. The company is currently loss‑making, with negative operating and free cash flow, and relies on a cost base that is heavy relative to revenue. Leverage is meaningful and liquidity is only moderately comfortable, so prolonged cash burn would increase pressure. At the same time, Zepp faces powerful global competitors and rapid innovation cycles, which could compress margins or dilute its differentiation if execution slips.
The outlook depends on whether Zepp can convert its innovation and ecosystem strategy into consistent profitability and cash generation before balance sheet pressures tighten. If it can scale subscription services, better leverage its technology, and bring operating costs in line with its revenue, its health‑focused platform could support a more durable business model. If not, high R&D needs, leverage, and competitive pressure may keep financial performance volatile and uncertain. Overall, the company appears to be in the middle of a strategic transition, with meaningful upside potential but also significant execution and financial risk.

CEO
Wang Huang
Compensation Summary
(Year )
Upcoming Earnings
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-09-16 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 4
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
FIL LTD
Shares:625.76K
Value:$8.68M
MORGAN STANLEY
Shares:610.29K
Value:$8.46M
POINT72 ASSET MANAGEMENT, L.P.
Shares:577.97K
Value:$8.02M
Summary
Showing Top 3 of 51

